Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Insider Selling and Security Concerns Cloud N-Able’s Solid Earnings

Robert Sasse by Robert Sasse
August 22, 2025
in Stocks
0
N-Able Stock
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Recent substantial stock sales by two key executives at N-Able are sending concerning signals to the market, despite the company posting quarterly results that surpassed analyst expectations. This activity raises questions about internal confidence in the cloud security specialist’s near-term prospects.

Executive Share Sales Raise Eyebrows

A significant reduction in shareholdings by top management has captured investor attention. On Wednesday, company supervisor Ann Johnson sold $266,173 worth of stock, slashing her position by a dramatic 71%. This followed a transaction the previous day by Executive Vice President Michael Adler, who disposed of shares valued at nearly $245,000. The financial community often interprets such large-scale insider selling as a potential lack of faith in the company’s short-term trajectory.

Strong Operational Performance Amidst Uncertainty

The firm’s operational health, detailed in its August 7th earnings release, presents a contrasting picture. N-Able reported a GAAP loss of $4 million for the quarter. However, its non-GAAP adjusted profit reached $20.4 million, comfortably exceeding forecasts. Revenue also outperformed, climbing nearly 10% year-over-year to $131.2 million. Management has reaffirmed an optimistic outlook for both the third quarter and the full fiscal year 2025, suggesting underlying business strength that appears at odds with the executives’ decision to sell.

Should investors sell immediately? Or is it worth buying N-Able?

Cybersecurity Flaws Pose Reputational Risk

Compounding these internal concerns is a critical security issue. Reports indicate that more than 1,000 N-Able servers currently remain vulnerable to two unpatched zero-day exploits, identified as CVE-2025-8875 and CVE-2025-8876. For a company whose core business is providing cybersecurity solutions, this vulnerability represents a significant reputational challenge. While the organization is actively urging clients to implement necessary updates, the potential damage to its brand as a trusted security partner could have lasting consequences.

Currently trading at $7.62, N-Able’s stock price sits more than 40% below its peak for the year. The convergence of substantial insider selling and serious security vulnerabilities introduces a critical question for investors: Is the company facing a deeper crisis of confidence that its solid financials cannot overcome?

Ad

N-Able Stock: Buy or Sell?! New N-Able Analysis from February 7 delivers the answer:

The latest N-Able figures speak for themselves: Urgent action needed for N-Able investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

N-Able: Buy or sell? Read more here...

Tags: N-Able
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Micron Stock

Micron Investors Face Competitive Threats Despite Strong Performance

Meta Stock

Meta's Hiring Pause Sends Shockwaves Through Tech Sector

Opendoor Stock

Opendoor Shares Plummet as Weak Outlook Overshadows Recent Gains

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com